Search results for "Hazard ratio"

showing 10 items of 691 documents

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergo…

2021

Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies. This retrospective analysis of the FIRE-3 study evaluated the evolution of body weight in patients with metastatic colorectal cancer (mCRC). FIRE-3 evaluated first-line FOLFIRI (folinic acid, fluorouracil and irinotecan) plus cetuximab or bevacizumab in mCRC patients with RAS-WT tumors (ie, wild-type in KRAS and NRAS exons 2-4). The prognostic and predictive relevance of early weight loss (EWL) regarding patient outcomes and treatment side effects were evaluated. Retrospective data on body weight during first 6 months of treatment were evaluated (N = 326). To correlate with efficacy endp…

Cancer Researchmedicine.medical_specialtyBevacizumabbusiness.industryColorectal cancerHazard ratioOdds ratiomedicine.diseaseGastroenterologyIrinotecanOncologyWeight lossInternal medicineFOLFIRIMedicinemedicine.symptomRisk factorbusinessmedicine.drugInternational Journal of Cancer
researchProduct

Trabectedin-Related Liver Toxicity in Soft Tissue Sarcoma Patients: Always a Good Reason to Discontinue the Treatment?

2014

ABSTRACT Aim: A transient increase in liver enzymes is a well described side effect developed by almost 40% of soft tissue sarcoma (STS) patients treated with trabectedin, often leading to treatment delays or discontinuation. We retrospectively analysed the correlation between trabectedin-related liver toxicity and treatment outcome. Methods: Data from a total of 113 patients receiving trabectedin administered at the dose of 1.5 mg/m2 iv 24 hours in 3 reference centers were evaluated. This exploratory analysis was performed to assess the impact of liver toxicity (grade 3-4 AST and ALT increases) on the trabectedin efficacy and outcome in STS patients. All the patients included had metastati…

Cancer Researchmedicine.medical_specialtyLiver toxicityAnthracyclineSide effectPopulationLiposarcomaGastroenterologyInternal medicinemedicineeducationTrabectedineducation.field_of_studybusiness.industrySoft tissue sarcomaHazard ratioHematologymedicine.diseaseSynovial sarcomaDiscontinuationSurgeryOncologyPremedicationSarcomabusinessmedicine.drugAnnals of Oncology
researchProduct

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

2021

Abstract Introduction/Background: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. Patients and Methods: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months. Results: The 2-year relapse incide…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTransplantation ConditioningHaploidentical transplantationGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/CancerGraft-versus-host diseaseInternal medicinemedicineHumansTransplantation HomologousComplete remissionComputingMilieux_MISCELLANEOUSAgedRetrospective StudiesAged 80 and overUnivariate analysisCMV positivitybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyTotal body irradiationPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseMinimal residual diseaseAllogeneic stem cell transplantationTransplantationLeukemia Myeloid AcuteGraft-versus-host diseaseOncologyTreatment-related mortalityAllogeneic stem cell transplantation; CMV positivity; Complete remission; Graft-versus-host disease; Haploidentical transplantation; Treatment-related mortalitybusiness
researchProduct

Identification of High-Risk Atypical Meningiomas According to Semantic and Radiomic Features

2020

Up to 60% of atypical meningiomas (World Health Organization (WHO) grade II) reoccur within 5 years after resection. However, no clear radiological criteria exist to identify tumors with higher risk of relapse. In this study, we aimed to assess the association of certain radiomic and semantic features of atypical meningiomas in MRI with tumor recurrence. We identified patients operated on primary atypical meningiomas in our department from 2007 to 2017. An analysis of 13 quantitatively defined radiomic and 11 qualitatively defined semantic criteria was performed based on preoperative MRI scans. Imaging characteristics were assessed along with clinical and survival data. The analysis include…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTumor resectionlcsh:RC254-282survivalArticleWorld healthResection03 medical and health sciences0302 clinical medicineatypical meningiomamedicineUnivariate analysisbusiness.industryHazard ratiopredictionOdds ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalOncologyradiomics030220 oncology & carcinogenesisRadiologybusiness030217 neurology & neurosurgeryCancers
researchProduct

Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment

2021

Abstract Aim This study investigated how material deprivation in Italy influences the stage of hepatocellular carcinoma (HCC) at diagnosis and the chance of cure. Methods 4114 patients from the Italian Liver Cancer database consecutively diagnosed with HCC between January 2008 and December 2018 were analysed about severe material deprivation (SMD) rate tertiles of the region of birth and region of managing hospitals, according to the European Statistics on Income and Living Conditions. The main outcomes were HCC diagnosis modalities (during or outside surveillance), treatment adoption and overall survival. Results In more deprived regions, HCC was more frequently diagnosed during surveillan…

Cancer Researchmedicine.medical_specialtySettore MED/12 - GastroenterologiaDeprivationbusiness.industryHepatocellular carcinomaPrognosiHazard ratioDeprivation; Hepatocellular carcinoma; Overall survival; Prognosis; Social determinants of healthmedicine.diseasePrognosisSocial determinants of healthOncologyInternal medicineHepatocellular carcinomamedicineOverall survivalOverall survivalSocial determinants of healthStage (cooking)businessLiver cancerSocioeconomic status
researchProduct

Abstract LB-146: A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P …

2013

Abstract Background: AZD8931 is an oral, equipotent inhibitor of EGFR, HER2, and HER3 signaling. Preclinical evidence indicates that AZD8931 may be particularly potent when HER signaling is ligand driven, which is thought to be the signaling mechanism that is more prevalent in low HER2-expressing BC. Methods: In this double-blind multicenter phase II study, women with low HER2- expressing locally advanced or metastatic BC (ineligible by HER2 status for either trastuzumab or lapatinib) were randomized 1:1 to AZD8931 40mg bid + P (90mg/m2; d1, 8 and 15, q4 weeks) or matched placebo + P (NCT00900627). The primary objective was prolonged progression-free survival (PFS; assessed by RECIST v1.1);…

Cancer Researchmedicine.medical_specialtybusiness.industryHazard ratioPlacebo-controlled studyPhases of clinical researchNeutropeniaPlacebomedicine.diseaseLapatinibGastroenterologySurgeryDiscontinuationOncologyInternal medicinemedicineAdverse effectbusinessmedicine.drugCancer Research
researchProduct

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study

2014

Purpose We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after disconinuation of LMWH, and the secondar…

Cancer Researchmedicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparinSettore MED/42 - Igiene Generale E ApplicataGroup BSettore MED/15 - Malattie Del SangueInternal medicineresidual vein thrombosis low molecular weight heparin cancer patientsmedicineeducationFirst episodeeducation.field_of_studybusiness.industrylow molecular weight heparinHazard ratioantivitamin K; low molecular weight heparin; nadroparinCancermedicine.diseaseThrombosisSurgerymedicine.anatomical_structureOncologynadroparinantivitamin Kbusiness
researchProduct

Risk factors for recurrence after robot-assisted radical hysterectomy for early-stage cervical cancer: a multicenter retrospective study

2020

This retrospective analysis aimed to assess the risk factors for recurrence in patients diagnosed with early-stage cervical cancer (&le

Cancer Researchmedicine.medical_specialtyrecurrenceSentinel lymph nodelcsh:RC254-282Article03 medical and health sciences0302 clinical medicineBiopsyrobotic surgerymedicineRadical HysterectomyStage (cooking)CàncerCancerCervical cancer030219 obstetrics & reproductive medicinemedicine.diagnostic_testoncological outcomeCirurgiabusiness.industryHazard ratioRetrospective cohort studymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitiesbody regionsOncologyEstudi de casos030220 oncology & carcinogenesisradical hysterectomyearly-stage cervical cancerAdenocarcinomaSurgeryRadiologyCase studiesbusiness
researchProduct

Association of Global Longitudinal Strain With Clinical Status and Mortality in Patients With Chronic Heart Failure.

2021

IMPORTANCE: Global longitudinal strain (GLS) is an emerging echocardiographic biomarker of cardiac function in heart failure (HF). Evidence from large-scale studies comprehensively investigating GLS for its association with clinical phenotypes and mortality in asymptomatic and symptomatic chronic HF is limited. OBJECTIVE: To assess the factors associated with GLS and its prognostic value in patients with chronic HF. DESIGN, SETTING, AND PARTICIPANTS: The observational, prospective MyoVasc cohort study enrolled 3289 individuals with asymptomatic to symptomatic HF between January 17, 2013, and April 27, 2018. The median follow-up was 3.2 years (interquartile range, 2.0-4.0 years). Participant…

Cardiac function curveMalemedicine.medical_specialty030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedOriginal InvestigationHeart Failurebusiness.industryHazard ratioPatient AcuityAtrial fibrillationHeartMiddle Agedmedicine.diseasePrognosisEchocardiographyHeart failureFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyJAMA cardiology
researchProduct

2021

AIMS Platelet indices have been associated with traditional cardiovascular risk factors, cardiovascular diseases and all-cause mortality. This study aimed to investigate the role of platelet count, mean platelet volume (MPV) and platelet-to-leukocyte ratio, including platelet-to-monocyte and platelet-to-lymphocyte ratio with cardiac function, heart failure (HF) phenotypes and clinical outcome, worsening of HF. METHODS AND RESULTS Univariate and multivariable linear and Cox regression analyses were used to investigate the associations between platelet indices, cardiac function and worsening of HF in 3250 subjects enrolled in the MyoVasc study. Higher MPV, lower platelet count, lower platelet…

Cardiac function curvemedicine.medical_specialtyPercentileEjection fractionbusiness.industryProportional hazards modelConfoundingHazard ratio030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineInternal medicineHeart failuremedicineCardiology030212 general & internal medicineMean platelet volumeCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct